C. Chabannon

D. Blaise, Wang LiNing, R. Devillier, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials

C. Chabannon, M. Gilabert, E. Mitry, 2021, Cancers.

European, Middle Eastern, and African Society for Biopreservation and Biobanking (ESBB). 2012 Conference Session on Biobanking in Emerging Countries.

R. Langer, R. Lawlor, P. Sluss, 2013, Biopreservation and biobanking.

Setting up a Prospective Thyroid Biobank for Translational Research: Practical Approach of a Single Institution (2004-2009, Pasteur Hospital, Nice, France).

N. Guevara, L. Castillo, J. Santini, 2011, Biopreservation and biobanking.

Detection of Epithelial Cells in Hematopoietic Organs of Patients with Breast Cancer

P. Viens, C. Arnoulet, C. Chabannon, 2001, Acta Haematologica.

Defining the impact of SARS-COV-2 on delivery of CAR T-cell therapy in Europe: a retrospective survey from the CTIWP of the EBMT

P. Ljungman, C. Chabannon, K. Mauff, 2021, Bone Marrow Transplantation.

Management of Adults and Children receiving CAR T-cell therapy: 2021 Best Practice Recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).

M. Kersten, J. Gribben, H. Einsele, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Considerations pertaining to cell collection and administration of industry-manufactured autologous CAR-T cells, in relation to French healthcare organization and regulations.

J. Larghero, C. Chabannon, 2018, Current research in translational medicine.

The calcineurin inhibitor and the intensity of the conditioning regimen may affect the occurrence of polyomavirus-associated hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide

D. Blaise, R. Devillier, S. Harbi, 2017, Bone Marrow Transplantation.

Lymphocyte subset reconstitution after unrelated cord blood or bone marrow transplantation in children

Y. Bertrand, C. Chabannon, A. Loundou, 2011, British journal of haematology.

Combining systemic and locally applied cellular therapies for the treatment of systemic sclerosis

C. Chabannon, A. Daumas, A. Benyamine, 2021, Bone Marrow Transplantation.

New developments in the use of apheresis to collect haematopoietic cells for cell transplantation and cell therapies

C. Chabannon, C. Faucher, A. Granata, 2016 .

Regulation of advanced therapy medicinal products will affect the practice of haematopoietic SCT in the near future: a perspective from the EBMT cell-processing committee

C. Chabannon, I. Slaper-Cortenbach, M. Lowdell, 2015, Bone Marrow Transplantation.

Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)

M. Bar, G. Mufti, S. Grupp, 2019, Bone Marrow Transplantation.

Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.

M. Bar, G. Mufti, S. Grupp, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Function of Jam‐B/Jam‐C Interaction in Homing and Mobilization of Human and Mouse Hematopoietic Stem and Progenitor Cells

M. Arcangeli, R. Adams, G. Bidaut, 2014, Stem cells.

CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives

M. Perales, A. Nagler, M. Mohty, 2019, Leukemia.

Identification of hurdles in the development of cell-based therapies.

C. Chabannon, R. Gramignoli, A. Rotolo, 2020, Cytotherapy.

Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019

S. Montoto, A. Gennery, N. Kröger, 2019, Bone Marrow Transplantation.

Feasibility of High Dose Melphalan (140 mg/m2) and Peripheral Blood Stem Cell Support as Consolidation for Patients over 60 Years with Acute Myeloid Leukemia in First Complete Remission

R. Bouabdallah, D. Blaise, D. Coso, 2003 .

JAM-B regulates maintenance of hematopoietic stem cells in the bone marrow.

M. Arcangeli, C. Schiff, R. Adams, 2011, Blood.

Transient detection of β-galactosidase activity in hematopoietic cells, following reinjection of retrovirally marked autologous blood progenitors in patients with breast or ovarian cancer receiving high-dose chemotherapy

D. Blaise, P. Viens, G. Gravis, 2002 .

Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation

S. Fröhling, P. Pedrazzoli, A. Santoro, 2020, ESMO Open.

[G-CSF in oncology].

P. Viens, C. Tarpin, C. Chabannon, 2006, Bulletin du cancer.

Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

P. Pedrazzoli, I. Yakoub-Agha, M. Mohty, 2022, Bone Marrow Transplantation.

T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes

D. Blaise, C. Carlo-Stella, R. Devillier, 2016, Bone Marrow Transplantation.

Use of the quality management system “JACIE” and outcome after hematopoietic stem cell transplantation

R. Brand, A. Gratwohl, H. Baldomero, 2014, Haematologica.

Role of growth factors in the control of leukemic cell proliferation.

C. Chabannon, P. Mannoni, 1994, Leukemia & lymphoma.

Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation.

F. Bertucci, P. Viens, C. Tarpin, 2016, European journal of cancer.

From clinical proof-of-concept to commercialization of CAR T cells.

C. Chabannon, B. Mfarrej, B. Calmels, 2018, Drug discovery today.

Structure of and Signalling Through Chimeric Antigen Receptor

C. Chabannon, C. Bonini, 2022, The EBMT/EHA CAR-T Cell Handbook.

Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey

I. Yakoub-Agha, M. Mohty, J. Snowden, 2022, Bone Marrow Transplantation.

Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT

D. Blaise, D. Coso, C. Chabannon, 2013, Bone Marrow Transplantation.

Bone marrow as stem cell source for allogeneic HLA-identical sibling transplantation following reduced-intensity preparative regimen.

D. Olive, D. Blaise, M. Mohty, 2003, Experimental hematology.

CAR-T cells: the narrow path between hope and bankruptcy?

S. Montoto, N. Kröger, A. Nagler, 2017, Bone Marrow Transplantation.

Accreditation and regulations in cell therapy

E. Rial‐Sebbag, C. Chabannon, I. Slaper-Cortenbach, 2016 .

Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation

D. Strunk, A. Nagler, F. Sánchez-Guijo, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial

F. Bertucci, D. Birnbaum, P. Finetti, 2022, Cancers.

Long‐term outcome after allogeneic stem‐cell transplantation with reduced‐intensity conditioning in patients with multiple myeloma

R. Bouabdallah, D. Blaise, D. Coso, 2013, American journal of hematology.

Are there candidates for high-dose chemotherapy in ovarian carcinoma?

F. Bertucci, P. Viens, C. Chabannon, 2012, Journal of experimental & clinical cancer research : CR.

Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: a phase II study

F. Bertucci, P. Viens, G. Gravis, 2002, Bone Marrow Transplantation.

Intensive sequential chemotherapy (ISC 95) with growth factors and blood stem cell support in high–intermediate and high-risk (IPI 2 and IPI 3) aggressive non-Hodgkin’s lymphoma: an oligocentric report on 42 patients

J. Rossi, R. Bouabdallah, L. Xerri, 1999, Leukemia.

Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a ‘donor’ versus ‘no donor’ comparison

D. Blaise, M. Mohty, D. Coso, 2009, Leukemia.

Hurdles to the Adoption of Gene Therapy as a Curative Option for Transfusion-Dependent Thalassemia

C. Chabannon, E. Angelucci, I. Thuret, 2022, Stem cells translational medicine.

Clinical outcome after front-line intensive sequential chemotherapy (ISC) in patients with aggressive non-Hodgkin's lymphoma and high-risk international prognostic index (IPI 3): final analysis of survival in two consecutive ISC trials.

R. Bouabdallah, D. Blaise, D. Coso, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Intensive Sequential Chemotherapy for Untreated Poor-Risk Non-Hodgkin’s Lymphoma

J. Rossi, R. Bouabdallah, D. Blaise, 1998 .

Non-myeloablative conditioning regimen before T-cell replete haploidentical transplantation with post-transplant cyclophosphamide for advanced Hodgkin's and non-Hodgkin's lymphomas.

A. Santoro, D. Blaise, C. Carlo-Stella, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma.

R. Bouabdallah, A. Santoro, D. Blaise, 2020, Blood advances.

High-dose sequential chemotherapy with stem cell support for non-metastatic breast cancer

F. Bertucci, D. Cowen, P. Viens, 1997, Bone Marrow Transplantation.

A review of 76 patients with myelodysplastic syndromes treated with danazol

C. Chabannon, M. Bost, L. Molina, 1994, Cancer.

WBMT Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy.

I. Yakoub-Agha, M. Mohty, M. Aljurf, 2022, Transplantation and Cellular Therapy.

Occult tumor cell contamination in patients with stage II/III breast cancer receiving sequential high-dose chemotherapy

F. Bertucci, P. Viens, C. Arnoulet, 2003, Bone Marrow Transplantation.

Public perceptions of the association between drug effectiveness and drug novelty in France during the COVID-19 pandemic

J. Mancini, C. Chabannon, J. Ward, 2022, Therapies.

rhG-CSF does not affect the phenotype of adult donor peripheral blood NK cells

D. Blaise, C. Chabannon, F. Lassailly, 2005, Bone Marrow Transplantation.

Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma

A. Santoro, D. Blaise, C. Carlo-Stella, 2018, Bone Marrow Transplantation.

Development of an enhanced B-specific lentiviral vector expressing BTK: a tool for gene therapy of XLA

J. Nunès, C. Chabannon, C. Tonnelle, 2008, Gene Therapy.

Aiolos and Ikaros: Regulators of lymphocyte development, homeostasis and lymphoproliferation

P. Debré, A. Rebollo, C. Chabannon, 2002, Apoptosis.

Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation

F. Bertucci, P. Viens, C. Tarpin, 2016, Bone Marrow Transplantation.

Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study

S. Montoto, N. Kröger, M. Robin, 2021, Haematologica.

Ancestim (r-metHuSCF) plus filgrastim and/or chemotherapy for mobilization of blood progenitors in 513 poorly mobilizing cancer patients: the French compassionate experience

J. Rossi, P. Moreau, C. Chabannon, 2011, Bone Marrow Transplantation.

Impact of viable CD45 cells infused on lymphocyte subset recovery after unrelated cord blood transplantation in children.

H. Chambost, C. Chabannon, A. Loundou, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

RNA extracted from blood samples with a rapid automated procedure is fit for molecular diagnosis or minimal residual disease monitoring in patients with a variety of malignant blood disorders.

M. Terrier, C. Chabannon, M. Mozziconacci, 2009, Biopreservation and biobanking.

M. Bar, G. Mufti, S. Grupp, 2021 .

Successful reconstitution of human hematopoiesis in the SCID-hu mouse by genetically modified, highly enriched progenitors isolated from fetal liver.

C. Chabannon, M. Firpo, L. Humeau, 1997, Blood.

Stage specific over-expression of the dominant negative Ikaros 6 reveals distinct role of Ikaros throughout human B-cell differentiation.

C. Chabannon, C. Tonnelle, F. Bardin, 2009, Molecular immunology.

A review of 76 patients with myelodysplastic syndromes treated with danazol

Daniel S. Holland, C. Chabannon, A. Avilés, 1994, Cancer.

A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma

R. Bouabdallah, L. Xerri, B. Chetaille, 2006, Bone Marrow Transplantation.

CD34+ cell enumeration in peripheral blood and apheresis samples, using two laboratory diagnostic kits or an institutional protocol

D. Blaise, P. Viens, C. Chabannon, 1999, Bone Marrow Transplantation.

OPTIMIZATION OF PERIPHERAL BLOOD STEM CELL COLLECTION BY LEUKOPHERESIS

J. Blache, D. Blaise, C. Chabannon, 1999, International Journal of Technology Assessment in Health Care.

Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: the number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recovery.

R. Bouabdallah, D. Blaise, P. Viens, 1996, Journal of hematotherapy.

Patient condition affects the collection of peripheral blood progenitors after priming with recombinant granulocyte colony-stimulating factor.

D. Blaise, C. Chabannon, D. Maraninchi, 1995, Journal of hematotherapy.

Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

P. Pedrazzoli, I. Yakoub-Agha, M. Mohty, 2022, Bone Marrow Transplantation.

Ex vivo manipulations alter the reconstitution potential of mobilized human CD34+ peripheral blood progenitors

M. Roncarolo, C. Chabannon, L. Humeau, 1999, Leukemia.

Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity

R. Bouabdallah, L. Xerri, D. Blaise, 2016, Bone Marrow Transplantation.

Physicians Poster Sessions

R. Bouabdallah, D. Blaise, L. Giordano, 2016, Bone Marrow Transplantation.

Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors.

D. Blaise, M. Mohty, V. Bardou, 2004, Blood.

High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation

R. Bouabdallah, D. Blaise, M. Mohty, 2000, Bone Marrow Transplantation.

Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome

R. Bouabdallah, A. Santoro, D. Blaise, 2020, Bone Marrow Transplantation.

Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation

R. Bouabdallah, A. Santoro, D. Blaise, 2016, Bone Marrow Transplantation.

Reduced-intensity versus myeloablative conditioning in cord blood transplantation for AML (40-60 years) across highly mismatched HLA barriers - On behalf of Eurocord and the Cellular Therapy & Immunobiology Working Party (CTIWP) of EBMT.

J. Sierra, D. Blaise, C. Chabannon, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation

M. Kattan, N. Kröger, A. Nagler, 2014, Bone Marrow Transplantation.

A case of polycythemia vera occurring in a patient with acute non-lymphoblastic leukemia (ANLL) in long-term first complete remission.

C. Chabannon, M. Bost, D. Hollard, 1994, Leukemia.

Biological Properties of HSC: Scientific Basis for HSCT

C. Chabannon, A. Aiuti, Serena Scala, 2018, The EBMT Handbook.

The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamide

A. Santoro, D. Blaise, C. Carlo-Stella, 2019, Bone Marrow Transplantation.

Ex vivo expansion of human hematopoietic progenitors and cells to support high-dose chemoradiation therapy: five years of clinical experience.

D. Blaise, P. Viens, C. Chabannon, 2000, Cytokines, cellular & molecular therapy.

Randomized study of 2 reduced‐intensity conditioning strategies for human leukocyte antigen‐matched, related allogeneic peripheral blood stem cell transplantation

D. Blaise, M. Mohty, V. Bardou, 2013, Cancer.

Modulations of dose intensity of doxorubicin and cyclophosphamide in association with G-CSF and peripheral blood stem cells in adjuvant chemotherapy for breast cancer: comparative evaluation of completion and safety of three intensive regimens

F. Bertucci, P. Viens, C. Chabannon, 2002, Bone Marrow Transplantation.

High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study.

K. Cornetta, D. Blaise, M. Shlomchik, 1998, British Journal of Cancer.

Phenotypic, molecular, and functional characterization of human peripheral blood CD34+/THY1+ cells.

C. Chabannon, L. Humeau, P. Mannoni, 1996, Blood.

A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the “on‐demand” scheme of administration at French autologous hematopoietic stem cell transplant programs

M. Mohty, C. Chabannon, N. Milpied, 2015, Transfusion.

Transplantation of allogeneic CD34+ blood cells in leukemia or lymphoma patients at high risk of GVHD

D. Blaise, C. Chabannon, F. Viret, 1999, Bone Marrow Transplantation.

Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT

R. Bouabdallah, D. Blaise, C. Oudin, 2013, Bone Marrow Transplantation.

[The Nice CHU biobank experience to collect patients' informed consent for research context (2004-2009)].

N. Guevara, L. Castillo, J. Santini, 2010, Annales de pathologie.

Granulocyte colony-stimulating factor-mobilized allogeneic peripheral blood stem cells for rescue graft failure after allogeneic bone marrow transplantation in two patients with acute myeloblastic leukemia in first complete remission.

A. Moine, C. Chabannon, F. Viret, 1995, Blood.

Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patients.

J. Blay, W. Brugger, P. Viens, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis.

F. Bertucci, D. Birnbaum, P. Finetti, 2008, Cancer research.

Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients

R. Bouabdallah, A. Santoro, D. Blaise, 2015, Haematologica.

Hematopoietic engraftment of XLA bone marrow CD34(+) cells in NOG/SCID mice.

C. Chabannon, C. Tonnelle, F. Le Deist, 2009, Cytotherapy.

Functional characterization of human CD34+ cells that express low or high levels of the membrane antigen CD111 (nectin 1)

P. Dubreuil, C. Chabannon, C. Tonnelle, 2003, Leukemia.

Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide

R. Fanin, P. Chiusolo, A. Santoro, 2022, Bone Marrow Transplantation.

Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting

L. Ruggeri, A. Velardi, A. Toubert, 2018, Bone Marrow Transplantation.

Opportunities and challenges associated with the evaluation of chimeric antigen receptor T cells in real-life.

C. Chabannon, C. Bonini, J. Kuball, 2020, Current opinion in oncology.

Essential requirements for setting up a stem cell processing laboratory

D. Niederwieser, F. Lanza, C. Chabannon, 2014, Bone Marrow Transplantation.

CD34+ progenitors are reproducibly recovered in thawed umbilical grafts, and positively influence haematopoietic reconstitution after transplantation

B. Esterni, H. Chambost, C. Chabannon, 2007, Bone Marrow Transplantation.

Assessing the HLA diversity of cord blood units collected from a birth clinic caring for pregnant women in an ethnically diverse metropolitan area

M. Gamerre, C. Chabannon, C. Picard, 2014, Transfusion.

[Peripheral blood stem cells].

C. Chabannon, 1996, Hematology and Cell Therapy.

Detection of different Ikaros isoforms in human leukaemias using real‐time quantitative polymerase chain reaction

J. Gabert, W. Nietfeld, C. Chabannon, 2000, British journal of haematology.

The first steps towards a diverse and inclusive EBMT: a position paper

S. Montoto, I. Yakoub-Agha, J. Snowden, 2022, Bone Marrow Transplantation.

Regulatory Aspects of ATMP Versus Minimally Manipulated Immune Cells

C. Chabannon, E. Mcgrath, 2018, The EBMT Handbook.

Stem Cell Source

C. Chabannon, A. Ruggeri, 2018 .

Positive selection of CD34+ peripheral blood progenitor cells in patients with low-grade lymphoid malignancies and bone marrow involvement.

R. Bouabdallah, D. Blaise, N. Vey, 1999, Hematology and cell therapy.

Overexpression of dominant-negative Ikaros 6 protein is restricted to a subset of B common adult acute lymphoblastic leukemias that express high levels of the CD34 antigen.

S. Granjeaud, C. Chabannon, C. Tonnelle, 2003, The hematology journal : the official journal of the European Haematology Association.

Expression of CD7 on normal human myeloid progenitors.

C. Chabannon, P. Wood, B. Torok-Storb, 1992, Journal of immunology.

Impact of the human leucocyte antigen (HLA)‐B leader peptide dimorphism and HLA‐A expression on outcomes of stem cell transplantation for sickle cell disease

C. Chabannon, R. Tamouza, E. Gluckman, 2021, British journal of haematology.

showed to be effective in preventing bleeding events.

D. Blaise, C. Oudin, C. Chabannon, 2013 .

Purification of monocytes from cryopreserved mobilized apheresis products by elutriation with the Elutra device.

C. Chabannon, J. Mcmannis, C. Lemarié, 2007, Journal of immunological methods.

Poor autologous mobilization status does not impact on hematological recovery but affects outcome after allogeneic stem cell transplant for lymphoma and myeloma

R. Bouabdallah, B. Esterni, D. Blaise, 2013, Leukemia and Lymphoma.

Reconstitution of natural killer cells in HLA-matched HSCT after reduced-intensity conditioning: impact on clinical outcome.

S. Granjeaud, D. Olive, D. Blaise, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study.

D. Blaise, C. Chabannon, D. Maraninchi, 1996, Bone marrow transplantation.

Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation

R. Bouabdallah, D. Blaise, R. Devillier, 2019, Bone Marrow Transplantation.

Autologous peripheral blood stem cell transplantation (PBSCT) in acute myeloid leukaemia (AML) in first complete remission (CR) a report of the BGMT cooperative group about 32 patients

P. Cony-Makhoul, D. Blaise, J. Reiffers, 2000 .

HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison.

D. Blaise, R. Devillier, S. Harbi, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party

R. Devillier, C. Chabannon, L. Castagna, 2022, Bone Marrow Transplantation.

Providing the Starting Material to the Manufacturer of an Approved and Commercially Available Autologous CAR-T Cell Treatment

C. Chabannon, M. Lozano, H. Bonig, 2022, The EBMT/EHA CAR-T Cell Handbook.

Analysis of a large single institution cohort of related donors fails to detect a relation between SDF1/CXCR4 or VCAM/VLA4 genetic polymorphisms and the level of hematopoietic progenitor cell mobilization in response to G-CSF

D. Blaise, J. Chiaroni, C. Chabannon, 2020, PloS one.

Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years

D. Blaise, R. Touzani, R. Devillier, 2018, Bone Marrow Transplantation.

Measuring the contribution of tumor biobanks to research in oncology: surrogate indicators and bibliographic output.

A. Cambon-Thomsen, Georges Dagher, B. Parodi, 2013, Biopreservation and biobanking.

Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies

P. Pedrazzoli, A. Toubert, C. Chabannon, 2018, Science Translational Medicine.

The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy.

S. Montoto, N. Kröger, I. Yakoub-Agha, 2020, Bone marrow transplantation.

Platelet recovery and transfusion needs after reduced intensity conditioning allogeneic peripheral blood stem cell transplantation.

D. Blaise, M. Mohty, P. Viens, 2010, Experimental hematology.

The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies

S. Montoto, N. Kröger, I. Yakoub-Agha, 2019, Bone Marrow Transplantation.

Implementation of JACIE accreditation results in the establishment of new indicators that unevenly monitor processes contributing to the delivery of hematopoietic SCT

C. Chabannon, F. Empereur, E. Mcgrath, 2013, Bone Marrow Transplantation.

Ten years after the first inspection of a candidate European centre, an EBMT registry analysis suggests that clinical outcome is improved when hematopoietic SCT is performed in a JACIE accredited program

A. Gratwohl, D. Niederwieser, F. Lanza, 2012, Bone Marrow Transplantation.

JACIE celebrates its 10-year anniversary with the demonstration of improved clinical outcome.

A. Gratwohl, D. Niederwieser, F. Lanza, 2011, Cytotherapy.

CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies.

N. Kröger, D. Blaise, C. Chabannon, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Risk factors of Ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients.

R. Bouabdallah, D. Blaise, C. Oudin, 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.

D. Blaise, R. Devillier, S. Harbi, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m2 intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia

D. Blaise, R. Devillier, S. Harbi, 2016, Leukemia & lymphoma.

Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies.

R. Bouabdallah, B. Esterni, D. Blaise, 2010, Experimental hematology.

Decreased RBCTs after reduced intensity conditioning allogeneic stem cell transplantation: predictive value of prior Hb level

R. Bouabdallah, D. Blaise, M. Mohty, 2004, Transfusion.

Impact of Pretransplant Donor and Recipient Cytomegalovirus Serostatus on Outcome for Multiple Myeloma Patients Undergoing Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation

R. Bouabdallah, D. Blaise, R. Devillier, 2012, Mediterranean journal of hematology and infectious diseases.

S. Montoto, N. Kröger, I. Yakoub-Agha, 2020, Bone Marrow Transplantation.

Correction: The challenge of COVID-19 and hematopoietic cell transplantation: EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy

S. Montoto, N. Kröger, I. Yakoub-Agha, 2020, Bone Marrow Transplantation.

Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years

N. Kröger, I. Yakoub-Agha, M. Mohty, 2021, Bone Marrow Transplantation.

Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial

S. Mallet, E. Jouve, L. Arnaud, 2014, Annals of the rheumatic diseases.

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

M. Kersten, H. Einsele, N. Kröger, 2019, Haematologica.

The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans

Eric Vivier, Zeren Gao, Betty Haldeman, 2009, The Journal of experimental medicine.

The B 7 family member B 7-H 6 is a tumor cell ligand for the activating natural killer cell receptor NKp 30 in humans

E. Yi, Wenfeng Xu, S. Levin, 2009 .

Manufacturing Natural Killer Cells as Medicinal Products

Eric Vivier, Christian Chabannon, D. Blaise, 2016, Front. Immunol..

Development of adaptive immune effector therapies in solid tumors.

P. Pedrazzoli, F. Lanza, C. Chabannon, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Hepatitis B virus reactivation in HBsAg-negative patients is associated with emergence of viral strains with mutated HBsAg and reverse transcriptase.

D. Coso, F. Barlesi, C. Chabannon, 2015, Virology.

Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg‐negative and anti‐HBc antibodies‐positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer

R. Bouabdallah, D. Coso, C. Chabannon, 2010, Journal of viral hepatitis.

Entecavir as a first‐line treatment for HBV reactivation following polychemotherapy for lymphoma

D. Coso, C. Chabannon, P. Colson, 2008, British journal of haematology.

The role of Ikaros in human erythroid differentiation.

C. Chabannon, C. Tonnelle, A. Murati, 2008, Blood.

Targeting natural killer cells and natural killer T cells in cancer

Eric Vivier, Christian Chabannon, D. Blaise, 2012, Nature Reviews Immunology.

Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.

D. Blaise, M. Mohty, P. Viens, 2003, Blood.

Betibeglogene Autotemcel Gene Therapy for Non-β0/β0 Genotype β-Thalassemia.

A. Schambach, T. Olson, P. Amrolia, 2021, The New England journal of medicine.

Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy.

V. Imbert, J. Peyron, C. Récher, 2016, Blood.

Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial

F. Bertucci, D. Birnbaum, P. Finetti, 2021, Genome Medicine.

Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells.

D. Birnbaum, L. Kanz, C. Hannum, 1996, Leukemia.

Comparable outcomes between unrelated and related donors after reduced‐intensity conditioning allogeneic hematopoietic stem cell transplantation in patients with high‐risk multiple myeloma

R. Bouabdallah, D. Blaise, D. Coso, 2012, European journal of haematology.

Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma

R. Bouabdallah, D. Blaise, M. Mohty, 2008, Bone Marrow Transplantation.

β-Galactosidase marker genes to tag and track human hematopoietic cells

C. Chabannon, C. Bagnis, P. Mannoni, 1999, Cancer Gene Therapy.

Human XCR1+ Dendritic Cells Derived In Vitro from CD34+ Progenitors Closely Resemble Blood Dendritic Cells, Including Their Adjuvant Responsiveness, Contrary to Monocyte-Derived Dendritic Cells

Even Fossum, C. Caux, Hong Liu, 2014, The Journal of Immunology.

Human XCR 1 + Dendritic Cells Derived In Vitro from CD 34 + Progenitors Closely Resemble Blood Dendritic Cells , Including Their Adjuvant Responsiveness , Contrary to Monocyte-Derived Dendritic Cells

Even Fossum, C. Caux, Hong Liu, 2014 .

Monocyte-Derived Dendritic Cells Their Adjuvant Responsiveness , Contrary to Resemble Blood Dendritic Cells , Including Progenitors Closely + Vitro from CD 34 Dendritic Cells Derived In + Human XCR

Even Fossum, Hong Liu, C. Chabannon, 2014 .

Ikaros Gene Expression and Leukemia

J. Gabert, C. Chabannon, C. Tonnelle, 2002, Leukemia & lymphoma.

Forced expression of the Ikaros 6 isoform in human placental blood CD34(+) cells impairs their ability to differentiate toward the B-lymphoid lineage.

C. Chabannon, A. Dalloul, C. Tonnelle, 2001, Blood.

Restriction of transgene expression to the B-lymphoid progeny of human lentivirally transduced CD34+ cells.

J. Imbert, C. Chabannon, C. Tonnelle, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

CD99 expressed on human mobilized peripheral blood CD34+ cells is involved in transendothelial migration.

C. Chabannon, C. Tonnelle, Marc Lopez, 2006, Blood.

Survey of Early Disapearance of BCR/ABL Fusion Transcript after Allogeneic or Autologous Stem Cell Transplantation for Chronic Myelogenous Leukemia

R. Bouabdallah, J. Gabert, D. Blaise, 2001, Leukemia & lymphoma.

Expression and recombination of the EGFP and EYFP genes in lentiviral vectors carrying two heterologous promoters.

C. Chabannon, C. Tonnelle, C. Torne-Celer, 2005, Cytotherapy.

Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies

D. Blaise, M. Mohty, S. Ederhy, 2022, Bone Marrow Transplantation.

T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors.

R. Bouabdallah, A. Santoro, D. Blaise, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma

R. Bouabdallah, A. Santoro, D. Blaise, 2017, Bone Marrow Transplantation.

Pre-clinical assessment of the Lovo device for dimethyl sulfoxide removal and cell concentration in thawed hematopoietic progenitor cell grafts.

C. Chabannon, P. Houzé, C. Lemarié, 2017, Cytotherapy.

Sepax-2 cell processing device: a study assessing reproducibility of concentrating thawed hematopoietic progenitor cells

C. Chabannon, A. Granata, C. Lemarié, 2022, Journal of Translational Medicine.

Early and fatal immune haemolysis after so-called ‘minor’ ABO-incompatible peripheral blood stem cell allotransplantation

D. Blaise, C. Chabannon, D. Maraninchi, 1997, Bone Marrow Transplantation.

CD146 Expression in Human Breast Cancer Cell Lines Induces Phenotypic and Functional Changes Observed in Epithelial to Mesenchymal Transition

M. Aurrand-Lions, C. Chabannon, C. Garulli, 2012, PloS one.

DNAM-1 and PVR Regulate Monocyte Migration through Endothelial Junctions

E. Devilard, L. Xerri, P. Dubreuil, 2004, The Journal of experimental medicine.

Comparison of a Selection of Rapid Automated DNA and RNA Extraction Technologies for Detection of Somatic or Constitutional Gene Abnormalities in Cancer Diagnosis

D. Birnbaum, L. Xerri, H. Sobol, 2007 .

Mobilisation of healthy donors with lenograstim and transplantation of HLA-genoidentical blood progenitors in 54 patients with hematological malignancies: a pilot study

D. Blaise, C. Chabannon, D. Maraninchi, 1998, Bone Marrow Transplantation.

Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia

N. Kröger, M. Labopin, D. Blaise, 2020, Leukemia.

Second neoplasms following high-dose chemotherapy and autologous stem cell transplantation for malignant lymphomas: a report of six cases in a cohort of 171 patients from a single institution.

R. Bouabdallah, D. Blaise, P. Viens, 1998, Leukemia & lymphoma.

Umbilical cord blood transplants facilitated by the French cord blood banks network. On behalf of the Agency of Biomedicine, Eurocord and the French society of bone marrow transplant and cell therapy (SFGM-TC)

J. Larghero, J. de Vos, J. Bay, 2021, Bone Marrow Transplantation.

Stem cell-stromal cell interactions.

C. Chabannon, B. Torok-Storb, 1992, Current topics in microbiology and immunology.

Early administration of recombinant erythropoietin improves hemoglobin recovery after reduced intensity conditioned allogeneic stem cell transplantation

R. Bouabdallah, B. Esterni, D. Blaise, 2005, Bone Marrow Transplantation.

Early establishment of chimerism in the B and T lymphoid lineages after transplantation of allogeneic mobilized blood cells in leukemic patients.

D. Blaise, C. Chabannon, D. Maraninchi, 1997, Transplantation.

Plerixafor in poor mobilizers with non-Hodgkin’s lymphoma: a multi-center time-motion analysis

M. Mohty, C. Chabannon, H. Ostermann, 2017, Bone Marrow Transplantation.

Features of large granular lymphocytes (LGL) expansion following allogeneic stem cell transplantation: a long-term analysis

D. Olive, D. Blaise, M. Mohty, 2002, Leukemia.

A matched‐pair analysis reveals marginally reduced CD34+ cell mobilization on second occasion in 27 related donors who underwent peripheral blood stem cell collection twice at the same institution

D. Blaise, R. Devillier, S. Harbi, 2019, Transfusion.

CD34(+) immunoselected cells for poor graft function following allogeneic BMT.

R. Bouabdallah, D. Blaise, M. Mohty, 2000, Cytotherapy.

National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine–busulfan–antithymocyte globulin conditioning regimen

D. Blaise, C. Oudin, C. Chabannon, 2014, Leukemia & lymphoma.

Cost–effectiveness of repeated aphereses in poor mobilizers undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation

D. Blaise, P. Viens, N. Vey, 2003, Leukemia.

Handling, processing and disposal of stem cell products in Europe: A survey by the cellular therapy and immunobiology working party of the European Society for Blood and Marrow Transplantation.

J. Snowden, H. Baldomero, F. Lanza, 2018, Cytotherapy.

Bone marrow and blood cells as alternative sources of hematopoietic progenitors after failure of a first collection. A single institution retrospective study.

D. Blaise, P. Viens, C. Chabannon, 1996, Transplantation.

Bone marrow processing for hematopoietic stem cell transplantation: recommendations of the SFGM-TC

J. D. Vos, I. Yakoub-Agha, C. Chabannon, 2015 .

Automated washing of autologous hematopoietic stem cell grafts after thawing does not impair engraftment

R. Bouabdallah, D. Coso, C. Chabannon, 2014, Bone Marrow Transplantation.

Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation

S. Montoto, A. Gennery, N. Kröger, 2018, Bone Marrow Transplantation.

M. Fays, D. Blaise, C. Chabannon, 2021, Bone Marrow Transplantation.

[Immunotherapy of acute myeloid leukemias: development of vaccines and cell therapy approaches].

D. Olive, D. Blaise, M. Mohty, 2003, Bulletin du Cancer.

Role of splenectomy in incidence and severity of acute graft-versus-host disease: a multicenter study of 157 patients.

J. Reiffers, C. Chabannon, J. Bosson, 1991, Bone marrow transplantation.

A. Moine, C. Chabannon, F. Viret, 1995 .

Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide.

A. Santoro, D. Blaise, C. Carlo-Stella, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor.

R. Bouabdallah, D. Blaise, R. Devillier, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide

R. Fanin, P. Chiusolo, A. Santoro, 2022, Bone Marrow Transplantation.

Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.

S. Montoto, N. Kröger, M. Labopin, 2019, The Lancet. Haematology.

An intra-patient comparison of blood cell separators Spectra and Optia in patients and donors undergoing blood mononuclear cell collections at a single institution for subsequent autologous or allogeneic hematopoietic cell transplantation reveals comparable collection efficiencies

C. Chabannon, A. Granata, C. Lemarié, 2016, Bone Marrow Transplantation.

Occurrence and severity of adverse events after autologous hematopoietic progenitor cell infusion are related to the amount of granulocytes in the apheresis product

B. Esterni, E. Deconinck, D. Coso, 2007, Transfusion.

Clinical experience with the delivery of thawed and washed autologous blood cells, with an automated closed fluid management device: CytoMate

R. Bouabdallah, D. Blaise, P. Viens, 2005, Transfusion.

Preclinical evaluation of an automated closed fluid management device: CytomateTM, for washing out DMSO from hematopoietic stem cell grafts after thawing

C. Chabannon, P. Houzé, B. Calmels, 2003, Bone Marrow Transplantation.

Monitoring for virus-specific T-cell responses and viremia in allogeneic HSCT recipients: a survey from the EBMT Cellular Therapy & Immunobiology Working Party

E. Weissinger, A. Velardi, C. Solano, 2023, Bone marrow transplantation.

Banking or Bankrupting: Strategies for Sustaining the Economic Future of Public Cord Blood Banks

Gregory Katz, J. Kurtzberg, J. Larghero, 2015, PloS one.

R. Bouabdallah, A. Santoro, D. Blaise, 2015, Cancer.

Cord blood collection and banking from a population with highly diverse geographic origins increase HLA diversity in the registry and do not lower the proportion of validated cord blood units: experience of the Marseille cord blood bank

M. Gamerre, C. Chabannon, J. Di Cristofaro, 2015, Bone Marrow Transplantation.

Increase the quality of banked cord blood units without limiting HLA diversity: how cord blood banks could face this dilemma

M. Gamerre, C. Chabannon, C. Picard, 2014, Transfusion.

Validation of a semi automatic device to standardize quantification of Colony-Forming Unit (CFU) on hematopoietic stem cell products.

C. Chabannon, C. Lemarié, B. Calmels, 2019, Cytotherapy.

Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs

B. Esterni, D. Blaise, M. Mohty, 2012, Bone Marrow Transplantation.

Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.

R. Bouabdallah, L. Xerri, D. Blaise, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft‐versus‐host disease in reduced‐intensity conditioning transplantation for hematologic diseases

R. Bouabdallah, B. Esterni, D. Blaise, 2013, Cancer.

Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma.

D. Blaise, C. Oudin, C. Chabannon, 2012, Experimental hematology.

Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients

R. Bouabdallah, D. Blaise, R. Devillier, 2018, Bone Marrow Transplantation.

The patient’s CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide

R. Bouabdallah, A. Santoro, D. Blaise, 2016, Bone Marrow Transplantation.

A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor

R. Bouabdallah, D. Blaise, D. Coso, 2014, American journal of hematology.

CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.

D. Olive, D. Blaise, M. Mohty, 2004, Experimental hematology.

Mother donors improve outcomes after HLA haploidentical transplantation: A Study by the Cellular Therapy and Immunobiology Working Party of the EBMT.

L. Ruggeri, A. Velardi, A. Toubert, 2022, Transplantation and cellular therapy.

JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement

J. Snowden, C. Chabannon, R. Saccardi, 2017, Bone Marrow Transplantation.

Validation of a flow cytometry-based method to quantify viable lymphocyte subtypes in fresh and cryopreserved hematopoietic cellular products.

C. Chabannon, C. Lemarié, B. Mfarrej, 2020, Cytotherapy.

Development of adaptive immune effector therapies in solid tumors.

P. Pedrazzoli, F. Lanza, C. Chabannon, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Autologous stem cell transplantation for acute myelogenous leukemia in first complete remission: a 6-year follow-up study of 101 patients from a single institution

R. Bouabdallah, D. Blaise, N. Vey, 2004, Bone Marrow Transplantation.

Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies

B. Esterni, P. Chevallier, D. Blaise, 2014, Haematologica.

Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients

R. Bouabdallah, D. Blaise, R. Devillier, 2019, Bone Marrow Transplantation.

The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus

S. Montoto, N. Kröger, I. Yakoub-Agha, 2020, Bone Marrow Transplantation.

Long-Term Outcome of Second Allogeneic Hematopoietic Stem Cell Transplantation as Salvage Therapy for Young Patients after Relapse or Graft Failure: Experience at a Single Institution

D. Blaise, M. Mohty, N. Vey, 2013 .

Clinical and economic comparison of lenograstim-primed blood cells (BC) and bone marrow (BM) allogeneic transplantation.

D. Blaise, P. Viens, J. Moatti, 1998, Bone marrow transplantation.

Study of megakaryocytic progenitors (CFU-MK) in human long-term bone marrow cultures (LTBMC): adjuvant effect of plasma from aplastic patients.

C. Chabannon, J. Léger, L. Molina, 1990, Experimental hematology.

Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation

D. Blaise, C. Oudin, C. Chabannon, 2012, American journal of hematology.

Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor

S. Montoto, N. Russell, E. Jantunen, 2019, Bone Marrow Transplantation.

Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation.

R. Brand, A. Gratwohl, H. Baldomero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preferential photoinactivation of leukemia cells by aluminum phthalocyanine.

C. Chabannon, M. Chanon, M. Julliard, 1998, Journal of photochemistry and photobiology. B, Biology.

Peripheral Blood Stem Cells versus Bone Marrow for T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma.

R. Bouabdallah, A. Santoro, D. Blaise, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Massive ascites of donor T-cell origin in a patient with acute GVHD after a reduced-intensity allograft for CLL

D. Blaise, M. Mohty, N. Vey, 2003, Bone Marrow Transplantation.

Use of the HLA-B leader to optimize cord blood transplantation

C. Chabannon, E. Petersdorf, T. Gooley, 2020, Haematologica.

Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation

F. Bertucci, P. Viens, C. Tarpin, 2017, Bone Marrow Transplantation.

Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

I. Yakoub-Agha, E. Tholouli, E. Deconinck, 2022, Haematologica.

Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation

F. Bertucci, D. Birnbaum, P. Finetti, 2019, Clinical Epigenetics.

Donor CD3(+) lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: single-center experience.

R. Bouabdallah, D. Blaise, C. Oudin, 2013, Experimental hematology.

The connected worlds of stem cell transplantation and HIV.

A. Wensing, C. Chabannon, J. Kuball, 2020, The lancet. HIV.

Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients.

J. Gribben, A. Filby, V. Imbert, 2016, Cancer research.

Priority Frequency and dynamics of ex-vivo AML-culture initiating cells reflect patients’ outcome.

J. Gribben, A. Filby, V. Imbert, 2015 .

Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin’s lymphoma

R. Bouabdallah, D. Blaise, C. Oudin, 2013, Bone Marrow Transplantation.

Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.

R. Bouabdallah, D. Blaise, C. Oudin, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[Comparative study of the costs for two hematopoietic cell specimen collections: cytapheresis and bone marrow collection].

J. Blache, P. Auquier, D. Blaise, 1996, Revue d'epidemiologie et de sante publique.

The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT

B. Esterni, D. Blaise, R. Devillier, 2012, Bone Marrow Transplantation.

CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines

F. Bertucci, D. Birnbaum, P. Finetti, 2009, Breast Cancer Research.

A pilot study of busulfan and melphalan as preparatory regimen prior to allogeneic bone marrow transplantation in refractory or relapsed hematological malignancies.

R. Bouabdallah, D. Blaise, N. Vey, 1996, Bone marrow transplantation.

Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial

M. Mohty, N. Russell, A. Ho, 2013, Haematologica.

Response to immunosuppressive treatment predicts outcome in patients with chronic graft-versus-host disease: a single-center analysis of longitudinal data.

M. Sormani, D. Blaise, C. Oudin, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor

N. Kröger, S. Iacobelli, N. Russell, 2019, Bone Marrow Transplantation.

Safety of Anti-NKG2A Blocking Antibody Monalizumab As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Study

D. Olive, D. Blaise, A. Chretien, 2021, Blood.

Current update on reduced intensity regimens for allogeneic stem cell transplantation

D. Olive, D. Blaise, M. Mohty, 2005, Hematology.

Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available

R. Bouabdallah, D. Blaise, D. Coso, 2015, Bone Marrow Transplantation.

Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide

D. Blaise, L. Giordano, C. Carlo-Stella, 2016, Bone Marrow Transplantation.

Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3+ cells

D. Blaise, R. Devillier, S. Harbi, 2018, British journal of haematology.

Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML

D. Blaise, R. Devillier, S. Harbi, 2017, Bone Marrow Transplantation.

Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor

D. Olive, D. Blaise, R. Devillier, 2020, Cancers.

Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma

R. Bouabdallah, A. Santoro, D. Blaise, 2017, Bone Marrow Transplantation.

Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE)

M. Labopin, M. Mohty, J. Snowden, 2023, Bone Marrow Transplantation.

Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-identical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

R. Bouabdallah, A. Santoro, D. Blaise, 2015, Mediterranean journal of hematology and infectious diseases.

Reduced-intensity conditioning regimen with in vivo T-cell depletion for patients with haematological malignancies: results using unrelated and sibling donors

B. Esterni, D. Blaise, D. Coso, 2014, Bone Marrow Transplantation.

Killer Cell Immunoglobulin-Like Receptor-Ligand Mismatch in Donor versus Recipient Direction Provides Better Graft-versus-Tumor Effect in Patients with Hematologic Malignancies Undergoing Allogeneic T Cell-Replete Haploidentical Transplantation Followed by Post-Transplant Cyclophosphamide.

D. Blaise, R. Devillier, S. Harbi, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Addition of plerixafor to G-CSF is useful to achieve efficient collection even in very poor mobilizers: hope for patients with diminished hematopoietic function

C. Chabannon, N. Milpied, P. Drillat, 2017, Bone Marrow Transplantation.

Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin’s lymphoma responding to prior salvage therapy

R. Bouabdallah, A. Santoro, D. Blaise, 2012, Haematologica.

T-Replete Haploidentical Allogeneic Transplantation Using Post-Transplantation Cyclophosphamide in Advanced Acute Myeloid Leukemia and Myelodysplastic Syndromes

A. Santoro, D. Blaise, R. Devillier, 2016 .

The Management of a Comprehensive Cancer Center during the First Six Months of the COVID-19 Pandemic in the South of France: Lessons from the Paoli-Calmettes Institute’s Experience

D. Blaise, P. Viens, N. Vey, 2021, Clinical hematology international.

Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Myeloid Leukemia (AML): Long Term Results of a “Donor” Versus “No Donor” Comparison.

D. Blaise, M. Mohty, D. Coso, 2007 .

Older age does not influence allogeneic peripheral blood stem cell mobilization in a donor population of mostly white ethnic origin.

D. Blaise, C. Chabannon, H. de Lavallade, 2009, Blood.

Early progenitor cells from human mobilized peripheral blood express low levels of the flt3 receptor, but exhibit various biological responses to flt3‐L

C. Chabannon, L. Humeau, P. Charbord, 1999, British journal of haematology.

Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP

A. Toubert, C. Chabannon, G. Oliveira, 2018, Bone Marrow Transplantation.

Low incidence of chronic GVHD after HLA‐haploidentical peripheral blood stem cell transplantation with post‐transplantation cyclophosphamide in older patients

D. Blaise, R. Devillier, S. Harbi, 2017, British journal of haematology.

Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available

R. Bouabdallah, D. Blaise, D. Coso, 2015, Bone Marrow Transplantation.

Immune reconstitution after blood cell transplantation.

D. Blaise, C. Arnoulet, C. Chabannon, 1997, Hematology and cell therapy.

Rescue of haemopoiesis by a combination of growth factors including stem-cell factor

D. Blaise, N. Vey, C. Chabannon, 2000, The Lancet.

Age at transplantation and outcome after autologous stem cell transplantation in elderly patients with multiple myeloma.

R. Bouabdallah, D. Blaise, M. Mohty, 2011, Hematology/oncology and stem cell therapy.

Secondary malignancies after high-dose chemotherapy in germ cell tumor patients: a 34-year retrospective study of the European Society for Blood and Marrow Transplantation (EBMT)

L. Mariani, P. Pedrazzoli, F. Lanza, 2018, Bone Marrow Transplantation.

Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) as Salvage Treatment for Relapsing Multiple Myeloma (MM): A “Donor” vs. “No Donor” Comparison.

R. Bouabdallah, D. Blaise, M. Mohty, 2006 .

Prospective Randomized Comparison of Reduced Intensity (FLU-BU-ATG) and Non-Myeloablative (FLU-TBI) Conditioning for Genoidentical Allo-SCT: a Clinical and economical Multicenter Itac Study.

D. Blaise, M. Mohty, J. Bay, 2009 .

[Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

I. Yakoub-Agha, J. Larghero, M. Deschamps, 2017, Bulletin du Cancer.

Protein Profiling of Human Breast Tumor Cells Identifies Novel Biomarkers Associated with Molecular Subtypes*S

F. Bertucci, D. Birnbaum, B. Esterni, 2008, Molecular & Cellular Proteomics.

Access to human tissues for research and product development

Sigrid Sterckx, Michiel Verlinden, Kris Dierickx, 2015, EMBO reports.

The EBMT Immune Effector Cell Nursing Guidelines on CAR-T Therapy: A Framework for Patient Care and Managing Common Toxicities

S. Montoto, M. Mohty, C. Chabannon, 2022, Clinical Hematology International.

Incidence of Acute Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation over Time: A Study from the Transplant Complications and Chronic Malignancies Working Party of the EBMT

S. Montoto, M. Robin, I. Yakoub-Agha, 2018, Blood.

Erratum: Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available (Bone Marrow Transplantation (2015) 50 (865-867) DOI: 10.1038/bmt.2015.22)

R. Bouabdallah, D. Blaise, D. Coso, 2015 .

Impact of CD34‐positive cell dose on outcome after peripheral blood stem cell allogeneic transplantation prepared with ATG‐based reduced intensity conditioning regimen

D. Blaise, R. Devillier, S. Harbi, 2017, American journal of hematology.

Consent for biobanking: assessing the understanding and views of cancer patients.

J. Mancini, N. Vey, C. Chabannon, 2011, Journal of the National Cancer Institute.

OP18. Optimization of peripheral blood stem cell collection (PBSC) by leukapheresis: a case of interaction between economic and clinical assessment of an innovation

C. Chabannon, D. Maraninchi, C. Faucher, 1997 .

1 Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer

F. Bertucci, D. Birnbaum, P. Finetti, 2017 .

Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer

F. Bertucci, D. Birnbaum, P. Finetti, 2011, Breast Cancer Research and Treatment.

[How to perform leukapheresis for procurement of the staring material used for commercial CAR T-cell manufacturing: A consensus from experts convened by the SFGM-TC].

I. Yakoub-Agha, C. Chabannon, L. Reppel, 2021, Bulletin du cancer.

Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study

F. Bertucci, P. Viens, C. Tarpin, 2016, Journal of Cancer.

Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT

A. Nagler, L. Ruggeri, A. Velardi, 2021, Bone Marrow Transplantation.

Early prognostic factors in septic shock cancer patients: a prospective study with a proteomic approach

J. Borg, C. Chabannon, L. Camoin, 2018, Acta anaesthesiologica Scandinavica.

Will CD34+ standardization solve all problems related to cell therapy?

C. Chabannon, D. Maraninchi, J. Moatti, 1997, Journal of Hematotherapy.

A neutralizing anti-TGF-beta1 antibody promotes proliferation of CD34+Thy-1+ peripheral blood progenitors and increases the number of transduced progenitors.

C. Chabannon, C. Bagnis, P. Mannoni, 1998, Experimental hematology.

Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)

M. Mohty, P. Moreau, C. Touzeau, 2023, Clinical Hematology International.

A fifteen‐year cytogenetic remission following interferon treatment in a patient with an indolent ETV6‐ABL positive myeloproliferative syndrome

C. Chabannon, M. Mozziconacci, D. Sainty, 2007, American journal of hematology.

The Role of Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (Allo-SCT) in Patients with Acute Myeloid Leukemia (AML): A Donor vs. No Donor Comparison.

D. Blaise, M. Mohty, D. Coso, 2004 .

Photophysical and Redox Properties of a Series of Phthalocyanines: Relation with Their Photodynamic Activities on TF‐1 and Daudi Leukemic Cells

C. Chabannon, M. Chanon, M. Julliard, 1996, Photochemistry and photobiology.

Monitoring for virus-specific T-cell responses and viremia in allogeneic HSCT recipients: a survey from the EBMT Cellular Therapy & Immunobiology Working Party

E. Weissinger, A. Velardi, C. Solano, 2023, Bone Marrow Transplantation.

A fifteen‐year cytogenetic remission following interferon treatment in a patient with an indolent ETV6‐ABL positive myeloproliferative syndrome

C. Chabannon, M. Mozziconacci, S. Gujral, 2007, American journal of hematology.

Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial

F. Bertucci, D. Birnbaum, P. Finetti, 2021, Genome Medicine.

[Academic cell therapy facilities are challenged by European regulation on advanced therapy medicinal products].

E. Rial‐Sebbag, C. Chabannon, G. Magalon, 2014, Medecine sciences : M/S.

PcG methylation of the HIST1 cluster defines an epigenetic marker of acute myeloid leukemia

S. Spicuglia, D. Grimwade, G. Bidaut, 2014, Leukemia.

Simulation as a Decision Support Tool - Estimating the Impacts of using RFID Technologies within Biobanks

Stéphane Dauzère-Pérès, Nabil Absi, Sylvain Housseman, 2009, HEALTHINF.

Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy.

F. Bertucci, S. Granjeaud, D. Birnbaum, 2006 .

RFID Technology and Electronic Tags to Identify Cryopreserved Materials

Christian Chabannon, C. Chabannon, Emmanuelle Bettendorf, 2005 .

Impact of antithymocyte globulin on the need for platelet transfusions during reduced-intensity conditioning administration before allogeneic stem cell transplantation.

D. Blaise, C. Oudin, C. Chabannon, 2013, Experimental hematology.

Clinical and hematological improvement in a patient receiving danazol therapy for myelofibrosis with myeloid metaplasia.

B. Pégourié, C. Chabannon, J. Sotto, 1990, Nouvelle revue francaise d'hematologie.

Metabolic effects of photodynamically induced apoptosis in an erythroleukemic cell line. A 31P NMR spectroscopic study of Victoria‐Blue‐BO‐sensitized TF‐1 cells

P. Cozzone, C. Chabannon, M. Julliard, 2000, International journal of cancer.

Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019

S. Montoto, A. Gennery, N. Kröger, 2019, Bone Marrow Transplantation.

Annual Conferences of the European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB): overview of 2011 and preview of 2012.

A. Cooreman, P. Riegman, Georges Dagher, 2012, Biopreservation and biobanking.

A gene expression signature identifies two prognostic subgroups of basal breast cancer

F. Bertucci, D. Birnbaum, P. Finetti, 2011, Breast Cancer Research and Treatment.

D. Blaise, R. Devillier, S. Harbi, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Immune Effector Cell-Associated Hematotoxicity (ICAHT): EHA/EBMT Consensus Grading and Best Practice Recommendations.

R. Houot, M. Kersten, J. Gribben, 2023, Blood.

R. Bouabdallah, A. Santoro, D. Blaise, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A new single-platform method for the enumeration of CD34+ cells.

C. Chabannon, C. Lemarié, B. Calmels, 2009, Cytotherapy.

GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10/10 HLA-matched unrelated allogeneic hematopoietic cell transplantation

D. Blaise, R. Devillier, S. Harbi, 2023, Bone Marrow Transplantation.

R. Bouabdallah, B. Esterni, D. Blaise, 2013, Cancer.

Production of ex vivo expanded hematopoietic cells and progenitors in a closed bioreactor, starting with a small volume marrow collection: A feasibility study in patients with poor-risk breast cancer and receiving high-doses of cyclophosphamide.

J. Blache, D. Blaise, P. Viens, 1999, International journal of oncology.

Randomized study of 2 reduced‐intensity conditioning strategies for human leukocyte antigen‐matched, related allogeneic peripheral blood stem cell transplantation

D. Blaise, M. Mohty, V. Bardou, 2013, Cancer.

Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party

A. Ganser, P. Dreger, J. Passweg, 2022, Journal for ImmunoTherapy of Cancer.

Decrease of lethal infectious complications in the context of causes of death (COD) after hematopoietic cell transplantation: COD-2 and COD-1 study of the Infectious Diseases Working Party EBMT

I. Yakoub-Agha, M. Mohty, J. Snowden, 2023, Bone Marrow Transplantation.

Reduced-intensity conditioning regimen with in vivo T-cell depletion for patients with haematological malignancies: results using unrelated and sibling donors

B. Esterni, D. Blaise, D. Coso, 2014, Bone Marrow Transplantation.

R. Bouabdallah, D. Blaise, R. Devillier, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.